The BD (Becton, Dickinson and Company) next-generation glass prefillable syringe (PFS) features new, tightened specifications for processability, cosmetics, contamination, and integrity. The new BD Effivax™ glass prefillable syringe was designed in collaboration with leading pharmaceutical companies to meet the complex, evolving needs of vaccine manufacturing.
The BD Effivax™ glass prefillable syringe will help customers meet the stringent demands of today’s vaccine manufacturing through design enhancements focused on fill/finish and container reliability. Through improved quality specifications, BD BD Effivax™ is designed to reduce the risk of line stoppage and improve the total cost of ownership, manufacturing capacity, and supply availability.
“As biopharmaceutical companies continue to rapidly grow their vaccine pipelines, demand for PFS is accelerating across the globe—given their proven ability to facilitate faster administration, support dose sparing and reduce vaccine waste,” says Eric Borin, worldwide president of BD Pharmaceutical Systems. “The launch of BD Effivax™ glass prefillable syringe strategically supports this growth and will create needed efficiencies in end-to-end production.”
The BD Effivax™ glass prefillable syringe will benefit from the $1.2 billion, four-year investment that BD announced in late 2020 to expand and upgrade manufacturing capacity and technology for PFS. As BD plans for the future of vaccinations, including mRNA and those used for COVID-19, the company remains committed to maintaining robust capacity for PFS to help reduce the time and labor required for vaccine preparation with traditional vial formats.